Home | All trials

[RDF data]
Trial NCT00000331

Resource URI: http://static.linkedct.org/resource/trials/NCT00000331
PropertyValue
linkedct:brief_title Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-3 - 6
linkedct:collaborator_agency <http://static.linkedct.org/resource/collabagency/8711>
linkedct:condition <http://static.linkedct.org/resource/condition/5932>
linkedct:condition <http://static.linkedct.org/resource/condition/9249>
linkedct:criteria Inclusion Criteria: Individuals must be healthy, non-drug dependent volunteers, be at least 18 years of age, and have no prior history of drug or alcohol abuse or dependence. Subjects must have had some minimal experience with opioids (e.g. at least two prior exposures) Exclusion Criteria: Individuals with evidence of an active DSM-IV Axis I psychiatric disorder (e.g. psychosis, manic-depressive illness, organic psychiatric disorders), significant medical illness (e.g., liver or cardiovascular disease) or pregnant female subjects are excluded from study participation.
linkedct:description not available at this time
linkedct:download_date Information obtained from ClinicalTrials.gov on December 30, 2009
linkedct:eligibility_gender Both
linkedct:eligibility_healthy_volunteers No
linkedct:eligibility_maximum_age 65 Years
linkedct:eligibility_minimum_age 18 Years
linkedct:enrollment 0 (xsd:int)
linkedct:firstreceived_date September 20, 1999
linkedct:id NCT00000331
rdfs:label Trial NCT00000331
linkedct:lastchanged_date November 3, 2005
linkedct:lead_sponsor_agency National Institute on Drug Abuse (NIDA)
linkedct:location <http://static.linkedct.org/resource/location/205451>
linkedct:nct_id NCT00000331
linkedct:number_of_arms 0 (xsd:int)
linkedct:number_of_groups 0 (xsd:int)
linkedct:official_title Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-3
linkedct:org_study_id NIDA-11160-6
linkedct:overall_official <http://static.linkedct.org/resource/overall_official/35001>
linkedct:overall_status Terminated
linkedct:oversight <http://static.linkedct.org/resource/oversight/2918>
foaf:page <http://clinicaltrials.gov/show/NCT00000331>
linkedct:phase Phase 2
linkedct:primary_outcomes <http://static.linkedct.org/resource/primary_outcomes/14202>
linkedct:primary_outcomes <http://static.linkedct.org/resource/primary_outcomes/17569>
linkedct:primary_outcomes <http://static.linkedct.org/resource/primary_outcomes/7277>
linkedct:secondary_id R01-11160-6
linkedct:source National Institute on Drug Abuse (NIDA)
linkedct:study_design Treatment, Double-Blind, Placebo Control
linkedct:study_type Interventional
linkedct:summary The purpose of this study is to assess the abuse liability and examine the reinforcing effects of intravenous buprenorphine and buprenorphine/naloxone combinations in healthy, non-drug dependent volunteers.
rdf:type linkedct:trials
linkedct:verification_date December 2002